+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of inhibitors against the potential ligandable sites in the active cholera toxin



Identification of inhibitors against the potential ligandable sites in the active cholera toxin



Computational Biology and Chemistry 55: 37-48



The active cholera toxin responsible for the massive loss of water and ions in cholera patients via its ADP ribosylation activity is a heterodimer of the A1 subunit of the bacterial holotoxin and the human cytosolic ARF6 (ADP Ribosylation Factor 6). The active toxin is a potential target for the design of inhibitors against cholera. In this study we identified the potential ligandable sites of the active cholera toxin which can serve as binding sites for drug-like molecules. By employing an energy-based approach to identify ligand binding sites, and comparison with the results of computational solvent mapping, we identified two potential ligandable sites in the active toxin which can be targeted during structure-based drug design against cholera. Based on the probe affinities of the identified ligandable regions, docking-based virtual screening was employed to identify probable inhibitors against these sites. Several indole-based alkaloids and phosphates showed strong interactions to the important residues of the ligandable region at the A1 active site. On the other hand, 26 top scoring hits were identified against the ligandable region at the A1 ARF6 interface which showed strong hydrogen bonding interactions, including guanidines, phosphates, Leucopterin and Aristolochic acid VIa. This study has important implications in the application of hybrid structure-based and ligand-based methods against the identified ligandable sites using the identified inhibitors as reference ligands, for drug design against the active cholera toxin.

(PDF emailed within 0-6 h: $19.90)

Accession: 058039670

Download citation: RISBibTeXText

PMID: 25698576

DOI: 10.1016/j.compbiolchem.2015.02.011


Related references

Immunocytochemical study on cholera toxin binding sites by monoclonal anti-cholera toxin antibody in neuronal tissue culture. Brain Research 242(2): 233-241, 1982

Monomers of cholera toxin b subunit are ineffective inhibitors of the binding of cholera toxin. Abstracts of the Annual Meeting of the American Society for Microbiology 84: ABSTRACT B9, 1984

Anti-idiotypic antibodies as probes of protein active sites: application to cholera toxin subunit B. Proceedings of the National Academy of Sciences of the United States of America 84(11): 3673-3677, 1987

Identification of cholera toxin-binding sites in the nucleus of intestinal epithelial cells. Febs Letters 242(2): 309-313, 1989

Unmasking of actual and potential receptor sites for cholera toxin in intestinal mucosal homogenates. Journal of Infectious Diseases 139(2): 235-236, 1979

The adjuvant effect of cholera toxin cholera toxin b subunit and glutaraldehyde modified cholera toxin on the mucosal immune response of rabbits to 2 acetylaminofluorene thyroglobulin conjugates. FASEB Journal 4(3): A500, 1990

Cholera toxin zonula occludens toxin and accessory cholera enterotoxin gene-negative Vibrio cholerae non-01 strains produce the new cholera toxin. Current Science (Bangalore) 70(12): 1041-1043, 1996

Identification of gtp binding proteins by adp ribosylation in the presence of cholera toxin pertussis toxin and botulinum toxin d in plasma membrane isolated from eggs and embryos of sea urchin. Development Growth & Differentiation 34(2): 211-222, 1992

Evaluation of purified cholera toxins and toxoids as immunizing agents against cholera and development of a new technique for measuring cholera toxin toxoid and anti toxin. U S Government Research & Development Reports 71(5): 43, 1971

Protection against experimental cholera in the rat. A study on the formation of antibodies against cholera toxin and desensitization of adenylate cyclase after immunization with cholera toxin. International Archives of Allergy and Applied Immunology 75(2): 143-148, 1984

Comparison of the glycolipid-binding specificities of cholera toxin and porcine Escherichia coli heat-labile enterotoxin: identification of a receptor-active non-ganglioside glycolipid for the heat-labile toxin in infant rabbit small intestine. Glycoconjugate Journal 11(6): 533-540, 1994

Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera. Faseb Journal 20(1): 130-132, 2005

Radiolabeled toxin for studying binding of cholera toxin and toxoids to intestinal mucosal receptor sites. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine 145(4): 1187-1191, 1974

Excretion of cholera toxin from Escherichia coli: a potential oral vaccine for cholera. Biochemical and Biophysical Research Communications 153(3): 967-972, 1988

Cholera toxin synergizes LPS- and IL-1 beta-induced PGE2 release: potential amplification systems in cholera. Lymphokine and Cytokine Research 10(6): 449-455, 1991